OpenAI acquires biotech agent startup Orchestra Bio to bolster Rosalind

OpenAI said Tuesday it acquired Orchestra Bio, a four-year-old AI biotech software startup, in an announcement on its website; deal terms weren’t disclosed. Backers reportedly put around $20 million total into the startup as of 2025, among them Andreessen Horowitz, Atria, and 8VC.

Orchestra builds AI agents that handle the operational details of drug discovery for biotech companies — from tracking finances to resolving clinical-trial scheduling conflicts. OpenAI plans to fold Orchestra’s team and technology into Rosalind, the company’s life-sciences AI model, and into the related Rosalind Workbench, a tool designed to support researchers as they plan experiments and interpret results. OpenAI says Rosalind has already attracted customers including Moderna and Novo Nordisk.

The deal fits a pattern of the largest AI labs — OpenAI and Anthropic chief among them — building increasingly specialized software for major industries such as pharma. Startups in those industries have voiced a standing worry that the labs could launch competing features at any time; in this case, OpenAI absorbed Orchestra rather than outcompeting it from outside.

Why it matters

Each acquisition like this narrows the field for independent AI-agent startups serving regulated industries, reinforcing how dependent that ecosystem has become on the capital and distribution of a handful of frontier labs.